NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE

Abstract

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

Claims

1. A compound for use in the manufacture of a medicament for reducing the symptoms of muscular dystrophy, wherein said compound has structural Formula I: ##STR00066## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of hydrogen, lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.1-3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form oxo or C.sub.3-6 saturated cycloalkyl; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amido, amino, aryl, aryloxy, aroyl, carbamate, carboxyl, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, nitro, oxo, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol.

2. The use as recited in claim 1, wherein R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.2-C.sub.3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form C.sub.3-6 saturated cycloalkyl; R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, aryloxy, aroyl, carbamate, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, trifluoroacetyl, C(O)-adamantyl, or benzoyl; if R.sub.1 is hydrogen, methyl, fluoro, or chloro, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 is methyl, then R.sub.9 is not hydrogen, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 and R.sub.6 are each methyl, then R.sub.9 is not hydrogen, acetyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is ethyl, then R.sub.9 is not acetyl; if said dashed line does not indicate a double bond, R.sub.1 is hydrogen or fluoro, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, then R.sub.9 is not hydrogen or acetyl; if R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, R.sub.3 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; and if R.sub.1 and R.sub.2 are each fluoro, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not acetyl.

3. The use as recited in claim 1, wherein R.sub.5 is selected from the group consisting of C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol.

4. The use as recited in claim 1, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

5. The use as recited in claim 4, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

6. The use as recited in claim 5, wherein R.sub.5 is selected from the group consisting of hydrogen, methyl, and ethyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen, acetyl, and C(O)CH.sub.2CH.sub.2CO.sub.2H.

7. The use as recited in claim 5, wherein R.sub.5 is selected from the group consisting of unsubstituted C.sub.2-C.sub.6 alkyl and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen, acetyl, and C(O)CH.sub.2CH.sub.2CO.sub.2H.

8. The use as recited in claim 5, wherein R.sub.5 is ethyl.

9. The use as recited in claim 1, wherein said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy.

10. The use as recited in claim 1, wherein said muscular dystrophy is Duchenne muscular dystrophy.

11. The use as recited in claim 1, comprising the administration of another therapeutic agent.

12. A compound for use in the manufacture of a medicament for reducing the symptoms of arthritis, wherein said compound has structural Formula I: ##STR00067## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of hydrogen, lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.1-3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form oxo or C.sub.3-6 saturated cycloalkyl; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amido, amino, aryl, aryloxy, aroyl, carbamate, carboxyl, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, nitro, oxo, perhaloalkoxy, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol; if R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not C(O)CH.sub.2CH.sub.2CO.sub.2H; if said dashed line does not indicate a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not C(O)CH.sub.2CH.sub.2CO.sub.2H; if said dashed line indicates a double bond, R.sub.1 is methyl, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not C(O)CH.sub.2CH.sub.2CO.sub.2H; if R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen or acetyl; if said dashed line does not indicate a double bond, R.sub.1 is fluorine, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen or acetyl; and if said dashed line does not indicate a double bond, R.sub.1 is methyl, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not acetyl.

13. The use as recited in claim 12, wherein R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.2-C.sub.3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form C.sub.3-6 saturated cycloalkyl; R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, aryloxy, aroyl, carbamate, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, perhaloalkoxy, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, trifluoroacetyl, C(O)-adamantyl, or benzoyl; if R.sub.1 is hydrogen, methyl, fluoro, or chloro, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 is methyl, then R.sub.9 is not hydrogen, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 and R.sub.6 are each methyl, then R.sub.9 is not hydrogen, acetyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is ethyl, then R.sub.9 is not acetyl; if said dashed line does not indicate a double bond, R.sub.1 is hydrogen or fluoro, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, then R.sub.9 is not hydrogen or acetyl; if R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, R.sub.3 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; and if R.sub.1 and R.sub.2 are each fluoro, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not acetyl.

14. The use as recited in claim 12, wherein R.sub.5 is selected from the group consisting of C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol.

15. The use as recited in claim 12, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

16. The use as recited in claim 15, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

17. The use as recited in claim 16, wherein R.sub.5 is selected from the group consisting of hydrogen, methyl, and ethyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen, acetyl, and C(O)CH.sub.2CH.sub.2CO.sub.2H.

18. The use as recited in claim 16, wherein R.sub.5 is selected from the group consisting of unsubstituted C.sub.2-C.sub.6 alkyl and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen, acetyl, and C(O)CH.sub.2CH.sub.2CO.sub.2H.

19. The use as recited in claim 18, wherein R.sub.5 is ethyl.

20. The use as recited in claim 12, comprising the administration of another therapeutic agent.

21. A compound for use in the manufacture of a medicament for reducing the symptoms of a NF-B-mediated disease, wherein said compound has structural Formula I: ##STR00068## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of hydrogen, lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.2-C.sub.3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form C.sub.3-6 saturated cycloalkyl; R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, aryloxy, aroyl, carbamate, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, trifluoroacetyl, C(O)-adamantyl, or benzoyl; if R.sub.1 is hydrogen, methyl, fluoro, or chloro, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 is methyl, then R.sub.9 is not hydrogen, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 and R.sub.6 are each methyl, then R.sub.9 is not hydrogen, acetyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is ethyl, then R.sub.9 is not acetyl; if said dashed line does not indicate a double bond, R.sub.1 is hydrogen or fluoro, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, then R.sub.9 is not hydrogen or acetyl; if R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, R.sub.3 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; and if R.sub.1 and R.sub.2 are each fluoro, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not acetyl.

22. The use as recited in claim 21, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxyl.

23. The use as recited in claim 22, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxyl.

24. The use as recited in claim 23, wherein R.sub.5 is selected from the group consisting of hydrogen, methyl, and ethyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen and acetyl.

25. The use as recited in claim 21, wherein said NF-B-mediated disease is selected from the group consisting of muscular dystrophy, arthritis, traumatic brain injury, spinal cord injury, sepsis, rheumatic disease, cancer atherosclerosis, type 1 diabetes, type 2 diabetes, leptospiriosis renal disease, glaucoma, retinal disease, ageing, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, ischemia/reperfusion, stroke, cerebral aneurysm, angina pectoris, pulmonary disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, Sjogren's syndrome, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, gut diseases, peritoneal endometriosis, skin diseases, nasal sinusitis, mesothelioma, anhidrotic ecodermal dysplasia-ID, behcet's disease, incontinentia pigmenti, tuberculosis, asthma, crohn's disease, colitis, ocular allergy, appendicitis, paget's disease, pancreatitis, periodonitis, endometriosis, inflammatory bowel disease, inflammatory lung disease, silica-induced diseases, sleep apnea, AIDS, HIV-1, autoimmune diseases, antiphospholipid syndrome, lupus, lupus nephritis, familial mediterranean fever, hereditary periodic fever syndrome, psychosocial stress diseases, neuropathological diseases, familial amyloidotic polyneuropathy, inflammatory neuropathy, parkinson's disease, multiple sclerosis, alzheimer's disease, amyotropic lateral sclerosis, huntington's disease, cataracts, and hearing loss.

26. The use as recited in claim 21, wherein said NF-B-mediated disease is asthma or chronic obstructive pulmonary disease.

27. The use as recited in claim 21, wherein said NF-B-mediated disease is Sjogren's syndrome.

28. The use as recited in claim 24, wherein said NF-B-mediated disease is asthma or chronic obstructive pulmonary disease.

29. The use as recited in claim 24, wherein said NF-B-mediated disease is Sjogren's syndrome.

30. The use as recited in claim 21, comprising the administration of another therapeutic agent.

31. A compound for use in the manufacture of a medicament for reducing the symptoms of a NF-B-mediated disease, wherein said compound has structural Formula I: ##STR00069## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.1-3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form oxo or C.sub.3-6 saturated cycloalkyl; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amido, amino, aryl, aryloxy, aroyl, carbamate, carboxyl, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, nitro, oxo, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol.

32. The use as recited in claim 31, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.5 is selected from the group consisting of unsubstituted C.sub.2-C.sub.6 alkyl and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

33. The use as recited in claim 32, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino, hydroxyl, and carboxyl.

34. The use as recited in claim 33, wherein R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen, acetyl, and C(O)CH.sub.2CH.sub.2CO.sub.2H.

35. The use as recited in claim 34, wherein R.sub.5 is ethyl.

36. The use as recited in claim 31, wherein said NF-B-mediated disease is selected from the group consisting of muscular dystrophy, arthritis, traumatic brain injury, spinal cord injury, sepsis, rheumatic disease, cancer atherosclerosis, type 1 diabetes, type 2 diabetes, leptospiriosis renal disease, glaucoma, retinal disease, ageing, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, ischemia/reperfusion, stroke, cerebral aneurysm, angina pectoris, pulmonary disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, Sjogren's syndrome, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, gut diseases, peritoneal endometriosis, skin diseases, nasal sinusitis, mesothelioma, anhidrotic ecodermal dysplasia-ID, behcet's disease, incontinentia pigmenti, tuberculosis, asthma, crohn's disease, colitis, ocular allergy, appendicitis, paget's disease, pancreatitis, periodonitis, endometriosis, inflammatory bowel disease, inflammatory lung disease, silica-induced diseases, sleep apnea, AIDS, HIV-1, autoimmune diseases, antiphospholipid syndrome, lupus, lupus nephritis, familial mediterranean fever, hereditary periodic fever syndrome, psychosocial stress diseases, neuropathological diseases, familial amyloidotic polyneuropathy, inflammatory neuropathy, parkinson's disease, multiple sclerosis, alzheimer's disease, amyotropic lateral sclerosis, huntington's disease, cataracts, and hearing loss.

37. The use as recited in claim 31, wherein said NF-B-mediated disease is asthma or chronic obstructive pulmonary disease.

38. The use as recited in claim 31, wherein said NF-B-mediated disease is Sjogren's syndrome.

39. The use as recited in claim 35, wherein said NF-B-mediated disease is asthma or chronic obstructive pulmonary disease.

40. The use as recited in claim 35, wherein said NF-B-mediated disease is Sjogren's syndrome.

41. The use as recited in claim 31, comprising the administration of another therapeutic agent.

42. A compound of structural Formula I: ##STR00070## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of hydrogen, lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said lower alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.2-C.sub.3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form C.sub.3-6 saturated cycloalkyl; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amino, aryl, aryloxy, aroyl, carbamate, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol. if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if R.sub.1 is hydrogen, methyl, CH.sub.2F, or fluoro, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, trifluoroacetyl, C(O)-adamantyl, or benzoyl; if R.sub.1 is hydrogen, methyl, fluoro, or chloro, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 is methyl, then R.sub.9 is not hydrogen, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.5 and R.sub.6 are each methyl, then R.sub.9 is not hydrogen, acetyl, or benzoyl; if said dashed line indicates a double bond, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, and R.sub.6 is ethyl, then R.sub.9 is not acetyl; if said dashed line does not indicate a double bond, R.sub.1 is hydrogen or fluoro, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each hydrogen, then R.sub.9 is not hydrogen or acetyl; if R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, and R.sub.8 are each hydrogen, R.sub.3 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not hydrogen, formyl, unsubstituted C.sub.1-C.sub.5 alkylacyl, or benzoyl; and if R.sub.1 and R.sub.2 are each fluoro, R.sub.3, R.sub.4, R.sub.7, and R.sub.8 are each hydrogen, R.sub.5 is methyl, and R.sub.6 is hydroxyl, then R.sub.9 is not acetyl.

43. The compound as recited in claim 42, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxy.

44. The compound as recited in claim 43, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.5 is selected from the group consisting of hydrogen, unsubstituted lower alkyl, and phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxy.

45. The compound as recited in claim 43, wherein R.sub.5 is selected from the group consisting of hydrogen, methyl, and ethyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen and acetyl.

46. The compound as recited in claim 45, wherein R.sub.5 is ethyl.

47. A compound as recited in claim 42 for use as a medicament.

48. A compound having structural Formula I: ##STR00071## or a salt thereof, wherein: said dashed line indicates an optional double bond; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, lower haloalkyl, and halogen; R.sub.5 is selected from the group consisting of C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, said C.sub.2-C.sub.8 alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, cycloalkyl, haloalkoxy, haloalkyl, heteroalkyl, heteroaryl, hydroxy, perhaloalkoxy, and thiol; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and lower alkyl, said lower alkyl being optionally substituted with one or more substituents selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, aryl, aryloxy, haloalkoxy, haloalkyl, heteroalkyl, hydroxy, and thiol; R.sub.7 and R.sub.8 are independently selected from the groups consisting of hydrogen, unsubstituted C.sub.1-3 alkyl, or R.sub.7 and R.sub.8 can be taken together to form oxo or C.sub.3-6 saturated cycloalkyl; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with one or more substituents selected from the group consisting of acyl, alkenyl, alkoxy, alkyl, alkylamino, alkylthio, alkynyl, amido, amino, aryl, aryloxy, aroyl, carbamate, carboxyl, cyano, cycloalkyl, halogen, haloalkoxy, haloalkyl, heteroalkyl, heterocycloalkyl, heteroaryl, hydrazinyl, hydroxy, mercaptyl, nitro, oxo, perhaloalkoxy, sulfonate, alkylsulfonyl, N-sulfonamido, S-sulfonamido, and thiol.

49. The compound as recited in claim 48, wherein R.sub.5 is selected from unsubstituted C.sub.2-C.sub.6 alkyl and phenyl.

50. The compound as recited in claim 49, wherein R.sub.1 and R.sub.3 are each hydrogen; R.sub.2 and R.sub.4 are each independently selected from the group consisting of hydrogen, methyl, and fluorine; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxy.

51. The compound as recited in claim 50, wherein R.sub.2 and R.sub.4 are each hydrogen; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; R.sub.7 and R.sub.8 are each hydrogen; and R.sub.9 is selected from the group consisting of hydrogen, acyl, and alkyl, said acyl and alkyl being optionally substituted with amino and hydroxy.

52. The compound as recited in claim 51, wherein R.sub.5 is ethyl or phenyl; R.sub.6 is selected from the group consisting of hydrogen, hydroxyl, and methyl; and R.sub.9 is selected from the group consisting of hydrogen and acetyl.

53. The compound as recited in claim 52, wherein R.sub.5 is ethyl.

54. A compound as recited in claim 48 for use as a medicament.

Description

EXAMPLE 1

(10S,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0191] ##STR00015##

Step 1

[0192] ##STR00016##

[0193] (10S,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one: Commercially available as Anecortave acetate. The title compound can be synthesized according to the procedure of Example 8, Step 2, substituting 2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate for 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate.

EXAMPLE 2

(10S,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0194] ##STR00017##

[0195] (10S,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one: The title compound can be synthesized according to the procedures of Example 3, Step 1 and Example 1, Step 1, substituting prednisolone acetate for hydrocortisone acetate.

EXAMPLE 3

2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

[0196] ##STR00018##

Step 1

[0197] ##STR00019##

[0198] 2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate: The title compound can be synthesized from hydrocortisone acetate according to the procedure disclosed in EP 0097328. 405 g (1 mol) of hydrocortisone acetate is added to a mixture of 2 liters of N,N-dimethylformamide and 350 ml of pyridine, and with stirring at room temperature, 260 g of methanesulfonyl chloride is added. The reaction mixture is heated, maintained at 80 to 85 c. for 1 hour, and then cooled to room temperature. Methanol (7 liters) is added. The precipitated crystals are separated by filtration, washed with methanol and water, and dried under reduced pressure to give the title compound.

EXAMPLE 6

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0199] ##STR00020##

Step 1

[0200] ##STR00021##

[0201] (10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one: A solution of the product from Example 7, step 2 in methylene chloride and methanol (1:3 methylene chloride/methanol) is stirred under an inert atmosphere and cooled in an ice bath. Aqueous potassium carbonate is added by syringe. The reaction is stirred at 5 C. for 2 hours. The reaction is then neutralized with 1N HCl and concentrated. After partitioning between water and methylene chloride, the product solution is dried over anhydrous magnesium sulfate, filtered and evaporated to give the title compound.

EXAMPLE 7

2-oxo-2-((10S,13S,16R)-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate

[0202] ##STR00022##

Step 1

[0203] ##STR00023##

[0204] 2-((10S,13S,16R)-10,13,16-trimethyl-3-oxo-7,8,12,13,15,16-hexahydro-3H-cyclopenta[a]phenanthren-17(6H,10H,14H)-ylidene)-2-(trimethylsilyloxy)ethyl acetate: (see K. P. Shephard, U.S. Pat. No. 4,975,536; Dec. 4, 1990; Preparation 1, col. 8) Into predried reactor 1 was added 36.64 grams (100 mmole) of 2-((10S,13S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate (commercial product from Pfizer). The starting material was dissolved in 200 ml of anhydrous tetrahydrofuran and 200 ml of anhydrous dichloromethane. Trimethylsilyl imidazole, (20.0 ml, 136 mmole), was added. This solution was cooled to 50 C. under a small nitrogen flow.

[0205] Into predried reactor 2 was added copper II propionate (2.10 grams, 10.0 mmole), 150 ml of anhydrous tetrahydrofuran, and anhydrous 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone. The mixture was cooled to 50 C. and methyl magnesium chloride (3M, 10.0 ml) was added dropwise over approximately 5 minutes. The mixture was stirred for approximately 10 minutes. The contents of reactor 2 were transferred to reactor 1 via cannula quickly (approximately 30 sec.), and reactor 2 was rinsed with 10 ml of anhydrous tetrahydrofuran and this was also cannulated into reactor 1. A pump was set up with methyl magnesium chloride (3M, 45.0 ml) and pumped into reactor 1 over 45 min (pump setting at 1.0 ml/min). Reactor 1 was stirred further at 50 C. for 1 hour, then warmed to 30 C. overnight.

[0206] Toluene (1 L) was added and the temperature brought to 0 C. The mixture was extracted with 2500 ml of 5% acetic acid (cold), then with 200 ml of 25% sodium chloride. The aqueous phases were back extracted with 300 ml of toluene. The combined toluene extracts were dried over magnesium sulfate, filtered, and concentrated to a viscous oil. Yield57.8 grams.

Step 2

[0207] ##STR00024##

[0208] 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate: The crude product from step 1 is dissolved in ethyl acetate, and slurried with aqueous 1N HCl until hydrolysis is complete. The aqueous acid is neutralized with aqueous potassium bicarbonate, and the ethyl acetate phase is dried, filtered, and concentrated to a semi-solid.

EXAMPLE 8

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0209] ##STR00025##

Step 1

[0210] ##STR00026##

[0211] 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate: A mixture of 3.3 g (8.6 mM) of 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate, chlorotris(triphenylphosphine)rhodium(I) (Wilkinson's Catalyst, 480 mg, 0.52 mM), triethylsilane (1.4 mL, 1.0 g, 8.8 mM) and methylene chloride (15 mL) was warmed to 40 C. and stirred until most of the starting material was gone, as determined by thin layer chromatography. The reaction was evaporated in vacuo and chromatographed on fine silica gel (600 g) in 10-15% ethyl acetate in methylene chloride. One fraction of 700 mL was collected, followed by twelve 200 mL fractions. A 1.0 g quantity of desired product (30% yield) was obtained by evaporation of fractions 6-12. (Starting material was obtained from fraction 13, 0.7 g, 20% recovery). NMR (500 MHz, CDCl.sub.3, TMS): 0.68 (s, 3H), 0.98 (d, 3H, J=6.5 Hz), 1.12 (m, 1H), 1.33 (s, 3H), 1.47 (m, 1H), 1.57 (m, 1H), 1.69 (m, 1H), 1.99 (m, 1H), 2.18 (s, 3H), 2.07-2.29 (m, 6H), 2.36 (d, 1H), 2.50 (m, 3H), 2.79 (m, 1H), 4.48 (d, 1H, J=17 Hz), 4.73 (d, 1H, J=17 Hz), 5.50 (s, 1H), 5.75 (s, 1H).

Step 2

[0212] ##STR00027##

[0213] (10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one: A solution of 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate (1.0 g, 2.6 mM) in methylene chloride (5 mL) and methanol (15 mL) was put under an inert atmosphere and cooled in an ice bath. 1 mL of 1 M aqueous potassium carbonate was added by syringe. The reaction was stirred at 5 C. for 2 h. The reaction was then neutralized with 1N HCl and concentrated. After partitioning between water and methylene chloride, the product solution was dried over anhydrous magnesium sulfate, filtered and evaporated. Crystallization from ethyl acetate yielded a first crop of 0.33 g product. NMR (500 MHz, CDCl.sub.3, TMS): 0.67 (s, 3H), 1.01 (d, 3H, J=7 Hz), 1.13 (m, 1H), 1.33 (s, 3H), 1.47-1.80 (m, 3, H), 2.00 (m, 1H), 2.06-2.24 (m, 6H), 2.37 (d, 1H), 2.45-2.60 (m, 3H), 2.82 (m, 1H), 3.30 (m, 1H), 4.20 (m, 2H), 5.50 (d, 1H, J=5 Hz), 5.76 (s, 1H).

EXAMPLE 15

(10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0214] ##STR00028##

Step 1

[0215] ##STR00029##

[0216] 2-((10S,13S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate: (Z)-2-((10S,13S,16R)-10,13,16-trimethyl-3-oxo-7,8,12,13,15,16-hexahydro-3H-cyclopenta[a]phenanthren-17(6H,10H,14H)-ylidene)-2-(trimethylsilyloxy)ethyl acetate is dissolved in methylene chloride and the mixture is cooled to zero degrees Celsius. A solution of m-chloroperbenzoic acid in methylene chloride is added dropwise and the mixture is stirred for 4 hours. The organic phase was washed with aqueous acetic acid and then aqueous bisulfite. The organic phase was concentrated and chromatographed on silica gel to yield the title compound.

Step 2

[0217] ##STR00030##

[0218] (10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one: Prepared according to Example 8, Step 2 substituting 2-((10S,13S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate for 2-oxo-2-((10S,13S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate.

EXAMPLE 16

(10S,13S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0219] ##STR00031##

EXAMPLE 19

(10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0220] ##STR00032##

EXAMPLE 20

(10S,13S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0221] ##STR00033##

EXAMPLE 21

(10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-propyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0222] ##STR00034##

EXAMPLE 22

(10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-propyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0223] ##STR00035##

EXAMPLE 23

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-16-propyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0224] ##STR00036##

EXAMPLE 24

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-16-propyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0225] ##STR00037##

EXAMPLE 25

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-16-phenyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0226] ##STR00038##

EXAMPLE 26

(10S,13S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-phenyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0227] ##STR00039##

EXAMPLE 27

(10S,13S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-phenyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0228] ##STR00040##

EXAMPLE 28

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-16-phenyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0229] ##STR00041##

EXAMPLE 29

(10S,13S,16S,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one

[0230] ##STR00042##

EXAMPLE 30

(10S,13S,16S,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0231] ##STR00043##

EXAMPLE 31

2-oxo-2-((10S,13S,16S,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate

[0232] ##STR00044##

EXAMPLE 32

(10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16,17-tetramethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

[0233] ##STR00045##

Step 1

[0234] ##STR00046##

[0235] 2-oxo-2-((10S,13S,16R,17S)-10,13,16,17-tetramethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate: A mixture of 2-((10S,13S)-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate (150 g) and copper propionate (1.9M in THF (90 ml) is cooled in an ice acetone bath. Methyl magnesium chloride (1.96M in THF, 240 ml) is added dropwise for 30 min. After 1 hour, the reaction is quenched with methyl iodide (100 g) in 200 ml THF. The reaction mixture is then partitioned with water and toluene. The separated organic phase is washed with water, dried over sodium sulfate and concentrated. The residue is crystallized from ether and hexane to give the title compound.

Step 2

[0236] ##STR00047##

[0237] 10S,13S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16,17-tetramethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one: 2-oxo-2-((10S,13S,16R,17S)-10,13,16,17-tetramethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate (144 g) is stirred in 1500 ml methanol and treated with sodium methoxide (25%, 5 ml) for 30 minutes. The mixture is partitioned between methylene chloride and sodium bicarbonate. The organic phase is separated and washed with sodium bicarbonate, dried over sodium sulfate, and concentrated to give the title compound.

[0238] The following compounds can generally be made using the methods described above. It is expected that these compounds when made will have activity similar to those that have been made and tested.

##STR00048## ##STR00049## ##STR00050## ##STR00051## ##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065##

[0239] The activity of the compounds in Examples 1-7 and 15-16 as NF-B modulators is illustrated in the following assays. The other compounds listed above, which have not yet been made and/or tested, are predicted to have activity in these assays as well.

Biological Activity Assay

In Vitro NF-kB Inhibitor Screening Assay

[0240] C2C12 skeletal muscle cells stably tranfected with a luciferase reporter construct regulated under multiple copies of the NF-kB response element (Panomics, Fremont, Calif.) were used to screen NF-kB inhibitors. These cells were maintained at 37 C. with 5% CO.sub.2 in a tissue culture incubator with Dulbecco's modified Eagle medium (DMEM) medium containing 10% Fetal bovine serum (FBS) (ATCC, Manassas, Va.), Penicillin 100 U/ml, Streptomycin 100 g/ml, and 100 g/ml Hygromysin B (Roche, Indianapolis, Ind.). Screening assays were performed in myoblasts (grown in medium containing 10% FBS) in duplicate 96 well plates at a cell concentration of 510.sup.4 cells per well in 100 ul volume. Cells were pretreated with various concentrations (0.01 ug/ml to 10 ug/ml) of compound for 24 hr duration before stimulating with tumor necrosis factor- (TNF-) (10 ng/ml) for another 24 hrs. Prednisolone was included in every plate tested as a positive control. After the completion of incubation cells were washed twice with PBS and lysed with cell lysis buffer to measure luciferase activity (Promega Corp, Madison, Wis.) using Centro LB 960 luminometer (Berthold technologies, GmbH & Co, Bad Wildbad, Germany). Relative luminescence units with TNF- stimulation in the absence of drugs were considered as 100% percent and data was represented as % inhibition relative to TNF- induced NF-kB activation.

[0241] Some of the compounds disclosed herein were tested in the C2C12 skeletal muscle cell luciferase assay and exhibited 100% inhibition at concentrations of 0.01, 0.1, and 1 ug/mL; 80-100% inhibition at concentrations of 0.01, 0.1, 1, and 10 ug/mL; 60-80% inhibition at concentrations of 0.01, 0.1, and 1 ug/mL; 40-60% inhibition at concentrations of 1 and 10 ug/mL; and 20-40% inhibition at concentrations of 10 ug/mL.

[0242] Cell viability was assayed in duplicate plates by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) (Sigma, Saint Louis, Mo.) as per manufacturer's protocols. Percent cell viability was calculated relative to untreated cells. There was not a significant decrease in cell viability (<80%) for any of compounds tested at any of the doses (0.01, 0.1, 1, and 10 ug/mL) tested.

Inhibition of NF-kB Nuclear Translocation

[0243] Inhibition of TNF- induced NF-kB activation was confirmed by nuclear translocation immunofluorescence assay. C2C12 cells were grown on cover slips and treated with TNF- and compound at optimal concentrations as described above. Cells were fixed with acetone and stained with a rabbit anti-NF-kB (p60) antibody/anti-rabbit Texas red (Santa Cruz Biotech, Inc, Santa Cruz, and CA) and counterstained with 4, 6-Diamidino-2-phenylindole HCl (DAPI) (Invitrogen, CA) to visualize the nuclei. Some of the compounds disclosed herein were tested in the nuclear translocation immunofluorescence assay and blocked TNF- induced NF-kB nuclear translocation.

In Vivo Mdx Mouse Model of Dystrophy

[0244] Separate groups (n=12-14) of mdx mice were treated with prednisolone (5 mg/kg/day; per oral in feed), Example 1 (20 and 40 mg/kg/day; per oral in feed) and Example 2 (20 and 40 mg/kg/day; per oral in feed) for 3 months. All mice underwent 30 min biweekly treadmill exercise during the treatment duration to unmask the mild disease phenotype of mdx mouse model.

Effect on Body Weight (BM)

[0245] Prednisolone treated mice showed significantly lower body weight (P<0.05) than untreated mice at 33.8 weeks age. Mice treated with some of the compounds disclosed herein at 20 and 40 mg/kg/day dosages gained significantly more body weight and gastrocnemius muscle mass than untreated mice.

Effect on In Vivo Motor Coordination and Strength

[0246] Motor coordination and strength were assessed using Rota-rod (Ugo Basile, VA, Italy) testing. Briefly, mice were trained on the rota-rod for two days before collecting data. Each acclimatization session consisted of four training sessions, 2 per day and each session lasting 120 seconds at a speed of 5 rpm). Each trial consisted of placing the mice on the rod at 10 rpm for 60 seconds (stabilizing period) followed by an acceleration from 10 rpm to 40 rpm within the first 25 seconds until the animal fell from the rod or until 180 seconds are reached. If the animals fell during the stabilizing period, they were placed back on the rod to complete the session. The total testing time was 240 seconds (60 seconds stabilization time and 180 seconds test time). Each trial was performed twice a day (2 hour interval between sessions) for 3 consecutive days. The latency to fall (seconds) was recorded and all six scores were averaged per mouse. The average data was expressed as latency to fall (in seconds) for each group mice at 3 age groups. The ability of untreated mice to stay on the rod did not change significantly with time. Mice treated with some of the compounds disclosed herein at 20 and 40 mg/kg/day dosages showed increased latency to fall at 12, 24, or 36 weeks. In some instances, latency to fall was decreased or unchanged, increased by 0-10%, increased by 10-20%, increased by 20-30%, or increased by 30-40%.

Effect on In Vitro Force Contractions:

[0247] The distal tendon of the extensor digitorum longus (EDL) muscle was tied securely to the lever arm of a servomotor/force transducer (model 305B, Aurora Scientific, Richmond Hill, ON, Canada) and the proximal tendon to a tissue clamp. Muscles were stimulated between two platinum electrodes. With supramaximal stimulation of the muscle using single 0.2-ms square stimulation pulses for the EDL, muscle length was adjusted to the length (L.sub.o) that resulted in maximal twitch force. With the muscle held at L.sub.o using stimulation frequencies of 30, 50, 80, 100, 120 and 150 Hz, the maximum isometric tetanic force force (P.sub.o) developed during a 300 ms train of stimulation pulses was recorded for the EDL muscle. The muscle length was then measured with calipers and after removal of the muscle from the bath the mass of the muscle was determined. For each muscle, the optimum fiber length (L.sub.f) was calculated by multiplying L.sub.o by a previously determined L.sub.f/L.sub.o ratio of 0.45. Total muscle fiber cross-sectional area was determined by dividing the wet mass by the product of L.sub.f and the density of mammalian skeletal muscle (1.06 mg/mm.sup.3). Maximum isometric specific force (sP.sub.o) was determined by dividing P.sub.o by the total muscle fiber cross-sectional area. There was no statistically significant (P<0.05) difference in specific force between untreated and prednisolone groups. Mice treated with some of the compounds disclosed herein at 20 and 40 mg/kg/day dosages showed statistically significant (P<0.05) increased isometric specific force. In some instances, isometric specific force was decreased or unchanged, increased by 0-5%, increased by 5-10%, increased by 10-15%, or increased by 15-20%.

Histological Evaluations

[0248] Hematoxylin and Eosin staining of gastrocnemius muscle of untreated mdx mice show significant degeneration and inflammation. Skeletal muscle from Example 1- and Example 2-treated mice showed significant decrease in inflammation, degeneration, and increase in regenerating muscle fibers in comparison to untreated and prednisolone treated mdx mice. Continuous administration of prednisolone appeared to increase degeneration and decrease in regeneration of dystrophic skeletal muscle.

Glucocorticoid Receptor Binding Assay

[0249] To determine the receptor binding affinity of example compounds to the glucocorticoid receptor (GR), a ligand binding assay was performed using cDNA expression clones (Baculovirus) for human and mouse glucocorticoid receptor-alpha. Liver extracts containing different GR constructs were incubated with radiolabeled 3H-Dexamethsone (Amersham Pharmacia Biotech) and test compound in assay buffer (10 mM Tris-HCl, 1.5 mM EDTA, 10% glycerol, 1 mM dithiothreitol, and 20 mM sodium molybdate, pH 7.6). The amount of radioactivity was measured using a scintillation plate reader. Dexamethasone showed competitive binding with 3H-dexamethasone at micromolar concentrations. Some of the compounds disclosed herein were tested in the glucocorticoid receptor binding assay and found to have no significant (>75%) competitive binding to the glucocorticoid receptor at millimolar concentrations.

[0250] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.